


IN A WORLD WITH MULTIPLE BIOLOGICS AND BIOSIMILARS, KNOWLEDGE IS POWERFUL MEDICINE

abbvie

BIOLOGICS HAVE REVOLUTIONIZED THE TREATMENT OF MANY SERIOUS, CHRONIC AND LIFE-THREATENING DISEASES



Biologics are complex medicines made from living organisms or cells. Examples include vaccines, insulin, hormones and monoclonal antibodies¹




More than **350 MILLION PEOPLE** Worldwide have been treated with biologics for conditions such as diabetes, rheumatoid arthritis, Crohn's disease and certain cancers¹

BIOLOGICS ARE COMPLEX MEDICINES¹


COMPLEXITY BY THE NUMBERS:

ASPIRIN (CHEMICAL MEDICINE):




21 ATOMS

INSULIN (LESS COMPLEX BIOLOGIC):



788 ATOMS

MONOCLONAL ANTIBODY (MORE COMPLEX BIOLOGIC):





MORE THAN 20,000 ATOMS



Biologics are made by living organisms and are highly sensitive to manufacturing conditions



THE COMPLEX WORLD WITH MULTIPLE BIOSIMILARS






BIOSIMILARS ARE NOT GENERIC VERSIONS OF ORIGINATOR BIOLOGICS






The smallest change to the starting materials and manufacturing processes can make a significant difference in the complex structure and function⁴

IMMUNOGENICITY IS KEY TO DETERMINING THE SAFETY AND EFFICACY OF BIOSIMILARS⁵



*Extrapolation of immunogenicity data is only possible from high-risk to low-risk patient populations and in clinical settings⁹

SWITCHING FROM AN ORIGINATOR BIOLOGIC TO A BIOSIMILAR IS A CHANGE IN MEDICATION



REFERENCES

- 1 EuropaBio: Guide to Biologics - A Focus on Biosimilar Medicines, 2011
- 2 PhRMA: Medicines in Development: Biologics, 2013
- 3 Sekhon BP, Saluja V. Biosimilars: an overview. Biosimilars. 2011
- 4 Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002
- 5 FDA Guidance for Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. April 2015.
- 6 European Commission. What You Need to Know about Biosimilar Medicinal Products. 2013
- 7 Schellekens H et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2010
- 8 Emery P et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015
- 9 Weise M et al. Biosimilars: what clinicians should know. Blood 2012
- 10 Van Assche G et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012
- 11 Wolf D et al. Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons. ECCO 2015
- 12 Rubin DT et al. Analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents. ECCO 2015
- 13 Sokka T and Kautiainen H. SAT0174 Clinical Experience with Infliximab Biosimilar – Switch from Remicade. EULAR 2015
- 14 Kang HW et al. Efficacy and safety of infliximab's biosimilar (REMSIMA) for IBD. ECCO 2014
- 15 Danese S et al. ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). Journal of Crohn's and Colitis 2013
- 16 American College of Rheumatology Positioning Paper on Biosimilars. 2015

